SEQ-400
Pharmaceutical compound
From Wikipedia, the free encyclopedia
SEQ-400 is a vaccine against urinary tract infections (UTIs) which is under development for potential medical use.[1][2][3] It is a vaccine against the Escherichia coli FimH adhesin protein, which is essential for bacterial infection.[3] The vaccine is being developed by Sequoia Sciences.[1][2] As of September 2023, it is in phase 2 clinical trials.[1][2] SEQ-400 is being developed for potential approval and use in the United States.[1]
| Vaccine description | |
|---|---|
| Target | Escherichia coli |
| Clinical data | |
| Other names | SEQ400 |
| Routes of administration | Unspecified[1] |
